Pfizer CEO Sees Potential in Emerging Market for Alzheimer's Treatment. In a recent interview with the Wall Street Journal, Pfizer CEO Albert Bourla's counterpart, Ulf Kallenius, hinted at the possibility of expanding the company's focus on Alzheimer's treatment. Kallenius emphasized that any such move would need to be financially viable, suggesting that the market may be growing and could potentially contribute to the company's bottom line. As researchers continue to explore new treatments for the debilitating disease, pharmaceutical companies are reassessing their strategies to capitalize on this emerging niche.
Kallenius told the Wall Street Journal that any such move would have to make "business sense," adding that it may be "a growing niche" that could contribute to business results.
